Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events

Elicio Therapeutics, Inc.

2025-Q3 EPS reported -$2.09 vs consensus -$0.56 ▼ miss (-272.5%)

Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.
Raised ~$11.1M gross via ATM since Q3 start; cash $20.6M at Sep 30, extending runway through Q2 2026.
Q3 net loss $10.1M ($0.60/sh) vs $18.8M ($1.39) YoY; R&D expense down to $5.0M from $7.2M.
IDMC recommended continue Phase 2 without modifications; after DFS analysis, will request End of Phase 2 FDA meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.